The tweet was deleted by the author.
But we saved everything 🙂.
Edgewise Therapeutics announced its active participation in upcoming major scientific events focused on cardiovascular medicine. Representatives from the company will be attending the Hypertrophic Cardiomyopathy Scientific Sessions and the American Heart Association's Annual Meeting in New Orleans, Louisiana.
These events are set to showcase the latest breakthroughs and research in cardiovascular health, providing Edgewise Therapeutics an opportunity to engage with cutting-edge findings and collaborate with other experts in the field.
Edgewise Therapeutics’ active engagement at major cardiovascular forums aligns with its broader strategy to deepen its scientific and clinical footprint, as evidenced by the company’s landmark developments highlighted in its published data on a major Becker Muscular Dystrophy trial. These initiatives build upon the foundation established in recent quarters, including forthcoming disclosures such as the anticipated Q3 2025 results, underscoring the company’s ongoing commitment to both robust scientific advancement and transparent business performance.